TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03093181

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Washout / Standard Cleanser
Description: Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout / Standard Cleanser
Description: Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product
Description: Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.
Study: NCT03211767

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aged garlic extract
Description: Each capsule contains 600mg of aged garlic extract powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each capsule contains cellulose as a filler.
Study: NCT03093181

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive control cleanser
Description: Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive control moisturiser
Description: Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.
Study: NCT04499703

Intervention type: DEVICE
Intervention: RHMS-RTM
Description: Assessment of retinal thickness
Study: NCT02608957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Latella Knee Implant System
Study: NCT04499703

Intervention type: DEVICE
Intervention: RHMS-RTM
Description: Assessment of retinal thickness

Intervention type: DEVICE
Intervention: RHMS-RTM
Description: Assessment of retinal thickness

Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT
Description: Assessment of retinal structure

Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT
Description: Assessment of retinal structure

Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT
Description: Assessment of retinal structure
Study: NCT04616443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection
Description: Oncolytic Type 2 Herpes Simplex Virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HX008 injection
Description: Recombinant humanized anti-PD-1 monoclonal antibody of injection
Study: NCT03903172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Description: Abdominal binder
Study: NCT00746005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: 3 g fish oil (3078 mg) total EPA 1512 mg and total DHA 1026 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo, sunflower oil
Description: 3 g of sunflower oil
Study: NCT02821533

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TACE
Description: TACE is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin will be mixed with a mixture of Lipiodol and ethanol (LEM), which consists of 33% ethanol by volume in Lipiodol, in a ratio of 2mg cisplatin per mL of LEM, and delivered through catheters or microcatheters to the tumors until there is flow reduction at the tumor feeders. The total dose of cisplatin given in each treatment session is limited to 100mg (50mL LEM) in each treatment session. The usual volume of LEM delivered will be 20 - 30 mL.
Study: NCT03933488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994 Placebo
Description: TAK-994 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994 Placebo
Description: TAK-994 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994 Placebo
Description: TAK-994 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994 Placebo
Description: TAK-994 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994 Placebo
Description: TAK-994 placebo-matching tablets.
Study: NCT04525521

Intervention type: OTHER
Intervention: Hand sanitizer and hand washing
Description: All subjects will cleanse their hands with hand sanitizer, followed by hand washing with soap and water

Intervention type: OTHER
Intervention: Hand sanitizer and hand washing
Description: All subjects will cleanse their hands with hand sanitizer, followed by hand washing with soap and water
Study: NCT04149080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIM + polypropylene membrane
Description: After tooth extraction the socket will be filled with 1.2% simvastatin gel and covered with polypropylene membrane, which will be intentionally exposed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After tooth extraction the socket will be filled with gel and covered with polypropylene membrane, which will be intentionally exposed.
Study: NCT00622765

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsule twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R256918
Description: 5 mg capsule twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R256918
Description: 10 mg capsule twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R256918
Description: 15 mg capsule twice daily
Study: NCT04552197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64251330
Description: JNJ-64251330 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64251330
Description: JNJ-64251330 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64251330
Description: JNJ-64251330 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64251330
Description: JNJ-64251330 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64251330
Description: JNJ-64251330 tablet will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Tofacitinib tablets will be administered orally.
Study: NCT01279746

Intervention type: DEVICE
Intervention: Ultrasound compression of femoral and popliteal veins
Description: Bedside ultrasound compression of femoral and popliteal veins.
Study: NCT00774917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Numen
Description: Numen Co-Cr coronary stent implant
Study: NCT03876925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT053PTSA
Description: Patients will received oral CT053PTSA once daily until disease progression or intolerable toxicity or subject's withdrawal from treatment ,each cycle is defined as 28 days
Study: NCT00405301

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
Description: Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
Description: Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
Description: Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.
Study: NCT04159714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Optix contact lens
Description: Contact lens will be placed on the surface of the patient's eye and is to be used as a bandage
Study: NCT00576511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 4 mg o.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo o.d.
Study: NCT01776957

Intervention type: DEVICE
Intervention: Device: Intrauterine device (IUD)
Description: Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
Study: NCT03460041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: caudal magnesium sulphate added to bupivacaine for pain management

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmetedomedine
Description: Caudal dexmetedomedine added to bupivacaine for pain management

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Caudal bupivacaine for pain management
Study: NCT04023201

Intervention type: OTHER
Intervention: Nocturnal symptoms
Description: Parkinson's disease patients with or without nocturnal symptoms
Study: NCT02427009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone position for 1 hour after blood patch
Description: After performing a blood patch, the patient will be placed in a prone position for 1 hour. This applies to all blood patches required during her hospitalization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood patch
Description: And indicated in inclusion criteria, patients in this protocol will have at least 1 blood patch. The amount of blood to be injected into the peridural space is fixed at 20 ml, but can be less in case of pain.
Study: NCT01640977

Intervention type: PROCEDURE
Intervention: Open PLIF (posterior lumbar interbody fusion)
Description: The PLIF procedure achieves access to the degenerated disc from the back of the spine.

Intervention type: PROCEDURE
Intervention: MAS PLIF
Description: The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
Study: NCT01493713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluate the correlation of overall different objective response.
Description: Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)
Study: NCT00003819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TF(c)-KLH conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thomsen-Friedenreich antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: keyhole limpet hemocyanin
Study: NCT02055586

Intervention type: OTHER
Intervention: fluorine F 18 fluorothymidine
Description: Undergo FLT-PET/MRI

Intervention type: DEVICE
Intervention: positron emission tomography
Description: Undergo FLT-PET/MRI

Intervention type: DEVICE
Intervention: magnetic resonance imaging
Description: Undergo FLT-PET/MRI
Study: NCT05461040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optic capture
Description: optic capture of Intraocular lens without anterior vitrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-the-bag implantation of Intraocular lens
Description: in-the-bag implantation of Intraocular lens with anterior vitrectomy
Study: NCT04585919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paired Screening Intervention
Description: The intervention is the implementation of a paired outreach strategy to patients in need of colorectal cancer screening to offer FIT testing and to complete screening for social determinants of health. These screening activities are part of routine practice but the intervention that is being implemented is the paired outreach for both CRC screening and SDOH screening.
Study: NCT02551458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveillance and rescue surgery in cases of resectable loco-regional recurrence
Study: NCT03879070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle active and passive mobilization using an Ankle mobilization device
Description: The treatment consists in 20 rehabilitation sessions, 5 times/week for 4 weeks. The device is capable of generating ankle dorsi/plantarflexion movements using two activation modes: passive and assistive. In the passive mode the device generates a movement pattern which the patient follows passively without exerting any force on the device. During the assistive mode, the device follows the active movement of the patient. During the intervention, these two modes will be alternated.
Study: NCT02432599

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F18-choline PET examination
Description: F18-choline PET examination will be performed before surgery
Study: NCT02465450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101 (lenabasum)
Description: Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101 (lenabasum)
Description: Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101 (lenabasum)
Description: Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101 (lenabasum)
Description: Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
Study: NCT00411320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral steroid-dexamethasone
Description: 2 week steroid trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral steroid-dexamethasone
Description: 2 week steroid trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral steroid-dexamethasone
Description: 2 week steroid trial
Study: NCT00650962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cardiopulmonary resuscitation
Description: 10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm analysis
Description: Rhythm analysis as soon as AED is ready
Study: NCT02739126

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial EBUS biopsy
Description: Radial EBUS is an endobronchial USS which is used to obtain biopsies from a peripheral lung mass.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial EBUS biopsy
Description: Radial EBUS is an endobronchial USS which is used to obtain biopsies from a peripheral lung mass.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Types of Radial Ultrasound probes
Description: The Radial USS probe comes in two sizes. A thick USS probe that is 1.7mm and the thin USS is 1.4mm in diameter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Types of Radial Ultrasound probes
Description: The Radial USS probe comes in two sizes. A thick USS probe that is 1.7mm and the thin USS is 1.4mm in diameter.
Study: NCT02830139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Description: Normal saline 3000ml-4000ml, Cisplatin 60mg/m2, 5-Fu 1500mg/m2, 43°C, 60min, During surgery and 7 days after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical colorectal resection
Description: radical colorectal resection with lymphadenectomy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Radical colorectal resection
Description: radical colorectal resection with lymphadenectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin , Capecitabine
Description: XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxaliplatin , Capecitabine
Description: XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline , Cisplatin , 5-Fu
Study: NCT02005796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Study: NCT01253161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide Long Acting Release (LAR)
Description: Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
Study: NCT03945630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior Quadratus Lumborum Block
Description: Interfascial plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: No QLB
Study: NCT04201340

Intervention type: DEVICE
Intervention: DRI OCT Triton with SS-OCT Angio software
Description: The Topcon DRI OCT Triton with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes

Intervention type: DEVICE
Intervention: DRI OCT Triton with SS-OCT Angio software
Description: The Topcon DRI OCT Triton with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes

Intervention type: DEVICE
Intervention: Cirrus HD-OCT 5000
Description: The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes

Intervention type: DEVICE
Intervention: Cirrus HD-OCT 5000
Description: The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes

Intervention type: DEVICE
Intervention: TRC-50DX
Description: The TRC-50DX retinal camera images the fundus used for diagnostic purposes

Intervention type: DEVICE
Intervention: TRC-50DX
Description: The TRC-50DX retinal camera images the fundus used for diagnostic purposes
Study: NCT02430051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Adapted Dental Environment
Description: The SADE intervention includes adaptations such as dimmed lighting, moving projections on the ceiling (fish, bubbles), exposure to soothing music, and application of a butterfly vest with wings that wrap around the child to provide calming sensations.
Study: NCT04174898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human Mesenchymal Stem Cell (MSC) infusion therapy
Description: Subjects will be infused with 100million human MSCs
Study: NCT03419832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEAT Form
Description: The NEAT form consists of a clear and concise overview document containing information satisfying all elements of consent. This is made up of IRB-approved wording from the regular consent form. More detailed information, such as specific clinic measures are provided as additional material and are discussed during the consent process after the general overview has been provided with the NEAT form.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Form
Description: The regular IRB approved version.
Study: NCT02217501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Description: Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Description: Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
Study: NCT00675675

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Description: Habit Reversal Training plus functional assessment/intervention designed to identify and ameliorate tic triggers (antecedents) and maintaining consequences.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Minimal Contact Waitlist
Description: Bimonthly phone check-in to assess clinical status and enhance subject retention
Study: NCT02851225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedicine transmission of biological results
Description: telemedicine transmission of biological informations
Study: NCT02506517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib